SNYR_OUT_1 [2025-04-15 04:36:31 -0400] 3418 Bytes | 859 tokens | Cum: 859 tkns (10.74% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Synergy CHC (SNYR) hit my radar screen, up to 2.5800 from a prev close of 1.7900 Do you think its got more juice or is it lacking potential? It's 4:36:29 AM on Tue Apr 15, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Synergy CHC (SNYR)
IPO: 2013-11-07 (11 Years Ago)
Market Cap: $15,344,068
Shares Outstanding: 8,750,000
Industry: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Exchange: XNAS
Description: Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.

Here’s the first list of news for Synergy CHC:

Mar-31-25 08:00AM - Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial Results
Mar-20-25 04:05PM - Synergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call Information
Mar-03-25 04:05PM - Synergy CHC to Attend 37th Annual ROTH Conference
Dec-06-24 08:00AM - Synergy CHC Reports its Seventh Consecutive Quarter of Profitability and its Third Quarter 2024 Financial Results
Nov-26-24 04:05PM - Synergy CHC Corp. Announces Third Quarter 2024 Earnings and Conference Call Information
Oct-24-24 05:00PM - Synergy CHC Corp. Announces Closing of Initial Public Offering
Oct-22-24 07:25PM - Synergy CHC Corp. Prices $10.35 Million Initial Public Offering

I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-11-06T11:00:00Z - Outdoor Solar Furniture Market Expected to Reach USD 564.71 Mn by 2032, Growing CAGR at 15.47% From 2024-2032 | Introspective Market Research

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Synergy CHC (SNYR).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

Restrict all your responses to just 3 tokens until the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load more documents, reply with: `NEX`

SNYR_OUT_3 [2025-04-15 04:36:31 -0400] 1035 Bytes | 286 tokens | Cum: 1147 tkns (14.34% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T12:26:10Z - Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full ...
A2 - 2025-03-31T12:26:10Z - Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full ...
A3 - 2025-03-31T12:09:17Z - Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full ...
A4 - 2025-03-31T12:00:00Z - Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full ...
A5 - 2025-03-31T08:32:14Z - Earnings Scheduled For March 31, 2025 - Alpha Cognition (NASDAQ:ACOG), Aqua Metals (NASDAQ:AQMS)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SNYR_OUT_5 [2025-04-15 04:36:34 -0400] 1182 Bytes | 313 tokens | Cum: 1462 tkns (18.27% of 8k)
==========================================================================

Showing A1 (chunk 1 of 11): A1:
**Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial Results By Investing.com**Date: 2025-03-31Source: {'uri': 'za.investing.com', 'dataType': 'news', 'title': 'Investing.com South Africa'}URL: https://za.investing.com/news/press-releases/synergy-chc-reports-its-eighth-consecutive-quarter-of-profitability-and-its-fourth-quarter-and-full-year-2024-financial-results-93CH-3632905Appoints Jaime Fickett as Permanent Chief Financial Officer

WESTBROOK, Maine, March 31, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (Synergy or the Company), a provider of consumer health care and lifestyle products, is announcing its financial results for the three and twelve months ended December 31, 2024.

We are pleased to report another fantastic year. We had another full year of profitability, marking our eighth consecutive

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_7 [2025-04-15 04:36:37 -0400] 1182 Bytes | 273 tokens | Cum: 1737 tkns (21.71% of 8k)
==========================================================================

Showing A1 (chunk 2 of 11): profitable quarter"a testament to the continued strength of our business and the progress we achieved throughout 2024, said Jack Ross, CEO of Synergy. While our fourth quarter results were still impacted by retailer de-inventorying from our FOCUSfactor packaging transition, we saw sequential improvement, and this transition is behind us as we enter 2025. During 2024, we executed on several key initiatives, including the successful rebranding of FOCUSfactor, expanding our distribution footprint with BJ's Wholesale Club and Publix, conducting our ready-to-drink (RTD) product testing in Canada, and completing our Initial Public Offering in October 2024.

As we move into 2025, we are focused on returning Synergy to top and bottom-line growth. In the first quarter of 2025, we launched seven new products under our Flat Tummy brand in response to the growing interest in GLP-1 support products.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_9 [2025-04-15 04:36:38 -0400] 1182 Bytes | 291 tokens | Cum: 2030 tkns (25.37% of 8k)
==========================================================================

Showing A1 (chunk 3 of 11): Additionally, we are pleased to announce that Jaime Fickett has been appointed as our Chief Financial Officer, continuing her valuable leadership and financial expertise with Synergy. We remain excited about the opportunities ahead and confident in our ability to create long-term value for our shareholders.

Fourth Quarter 2024 Financial Summary vs. Same Year-Ago Period

2024 Financial Summary vs. Same Year-Ago Period

Recent Business Highlights

Fourth Quarter and Full Year 2024 Financial Results

Revenue in the fourth quarter of 2024 was $10.3 million, down 22% compared to $13.2 million in the fourth quarter of 2023. For the full year 2024, revenue was $34.8 million, down 19% compared to $42.8 million in 2023. The decreases were largely driven by a rebranding and de-inventorying of FOCUSfactor, which was the first rebranding since 2015, and a one-time return of a rotational item.

Gro

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_11 [2025-04-15 04:36:39 -0400] 1182 Bytes | 335 tokens | Cum: 2367 tkns (29.59% of 8k)
==========================================================================

Showing A1 (chunk 4 of 11): ss margin in the fourth quarter of 2024 was 63.3% compared to 82.3% in the fourth quarter of 2023. For the full year 2024, gross margin was 67.9%, down 712 basis points compared to 75.0% in 2023. The decrease was largely driven by a one-time gain to cost of sales in 2023 of $2.2 million. Without that gain, gross margin in the fourth quarter of 2023 would have been 65.3% and would have been 69.8% for the full year of 2023.

Operating expenses in the fourth quarter of 2024 were $5.1 million, a decrease of 20% compared to $6.4 million in the fourth quarter of 2023. For the full year 2024, operating expenses were $17.9 million, a decrease of 16% compared to $21.3 million in 2023. The lower operating expenses were driven by improved management of operating costs.

Income from operations for the fourth quarter of 2024 was $1.4 million compared to $4.4 million in the fourth quarter of 2023. For

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_13 [2025-04-15 04:36:39 -0400] 1182 Bytes | 341 tokens | Cum: 2710 tkns (33.88% of 8k)
==========================================================================

Showing A1 (chunk 5 of 11): the full year 2024, income from operations was $5.8 million compared to $10.8 million in 2023. The decline in operating income was due to a decrease in net sales due to the rebranding.

Net income in the fourth quarter of 2024 was $105.7 thousand compared to net income of $2.6 million in the fourth quarter of 2023. For the full year 2024, net income was $2.1 million compared to $6.3 million in 2023.

EBITDA (a non-GAAP financial measure) in the fourth quarter of 2024 was $1.7 million, compared to $4.5 million in the fourth quarter of 2023. For the full year 2024, EBITDA was $6.5 million compared to $10.8 million in 2023. The decrease was primarily due to the decrease in net revenue due to the rebranding.

Adjusted EBITDA (a non-GAAP financial measure) in the fourth quarter of 2024 was $2.8 million, up 1,033% compared to $(0.3) million in the fourth quarter of 2023. For the full year 202

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_15 [2025-04-15 04:36:40 -0400] 1182 Bytes | 321 tokens | Cum: 3033 tkns (37.91% of 8k)
==========================================================================

Showing A1 (chunk 6 of 11): 4, Adjusted EBITDA was $7.4 million compared to $6.1 million in 2023, an increase of 21%.

Balance Sheet and Cash Flow

As of December 31, 2024, Synergy had approximately $687.9 thousand in cash and cash equivalents, compared to $632.5 thousand in cash and cash equivalents as of December 31, 2023. As of December 31, 2024, Synergy had $33.0 million in total liabilities, compared to $39.5 million in total liabilities as of December 31, 2023, an improvement of $6.6 million.

As of December 31, 2024, Synergy had $1.7 million in inventory, compared to $3.7 million in inventory as of December 31, 2023.

Cash used in operating activities for the twelve months ended December 31, 2024 was $4.8 million compared to cash provided by operating activities of $421.7 thousand for the twelve months ended December 31, 2023. The decrease in cash provided by operating activities was primarily attributable t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_17 [2025-04-15 04:36:41 -0400] 1182 Bytes | 246 tokens | Cum: 3281 tkns (41.01% of 8k)
==========================================================================

Showing A1 (chunk 7 of 11): o lower net income and a significant increase in accounts receivable, other receivable, along with higher prepaid expenses and a decrease in accounts payable and accrued liabilities.

EBITDA

Along with this information, to assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

The following table reconciles net income to EBITDA (in millions of US dollars):

Adjusted EBITDA

The Company believes that the provision of this supplemental non-GAAP measure allows investors to evaluate the operational and fin

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_19 [2025-04-15 04:36:42 -0400] 1182 Bytes | 277 tokens | Cum: 3560 tkns (44.50% of 8k)
==========================================================================

Showing A1 (chunk 8 of 11): ancial performance of the Company's core business using similar evaluation measures to those used by management. The Company uses Adjusted EBITDA to measure its performance and prepare its budgets. Since Adjusted EBITDA is a non-GAAP financial performance measure, the Company's calculation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies; and should not be considered in isolation, as a substitute for, or superior to measures of financial performance prepared in accordance with GAAP.

The following table reconciles net income to Adjusted EBITDA (in millions of US dollars):

Conference Call

In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on March 31, 2025 with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of th

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_21 [2025-04-15 04:36:43 -0400] 1182 Bytes | 260 tokens | Cum: 3822 tkns (47.77% of 8k)
==========================================================================

Showing A1 (chunk 9 of 11): e call will be available on the Investor Relations section of Synergy's website. To access the call by phone, please go to this link (registration link) and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company's website.

About Synergy CHC Corp.

Synergy CHC Corp. is a provider of consumer health care and lifestyle products. Synergy's current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their weight management goals.

Forward Looking Statements

Certain statements

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_23 [2025-04-15 04:36:44 -0400] 1183 Bytes | 248 tokens | Cum: 4072 tkns (50.90% of 8k)
==========================================================================

Showing A1 (chunk 10 of 11): contained in this press release constitute "forward-looking statements." These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_25 [2025-04-15 04:36:45 -0400] 1055 Bytes | 285 tokens | Cum: 4359 tkns (54.49% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the audited condensed CONS financial statements an...

S2 - 2025-03-31 8-K Item 2.02. Results of Oper and Fin Cond.

On March 31, 2025, Synergy CHC Corp. (the Company) issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2024. A copy of the press release is furnished herewith...

S4 - 2024-12-06 10-Q PART IFIN INFO

Item 1. Fin Stmnts.

Synergy CHC Corp.

Condensed Interim Fin Stmnts

For the Nine Months Ended September 30, 2024 and 2023

Unaudited

(Expressed in U.S. Dollars)

MGT RESPONSIBILITY FOR FIN REPORTING CONDENS...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SNYR_OUT_27 [2025-04-15 04:36:46 -0400] 1181 Bytes | 234 tokens | Cum: 4595 tkns (57.44% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the audited condensed consolidated financial statements and the notes thereto contained elsewhere in this Annual Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements.

Overview

We are a provider of consumer health care, beauty, and lifestyle products. Our current brand portfolio consists of two core brands: FOCUSfactor, a clinically-tested brain health supplement (this study was performed independently and is not related to any FDA

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_29 [2025-04-15 04:36:49 -0400] 1181 Bytes | 236 tokens | Cum: 4833 tkns (60.41% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): -approved IND application) that has been shown to improve memory, concentration and focus and Flat Tummy, a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals.

Our managements discussion and analysis of our financial condition and results of operations are only based on our current business and should be read in conjunction with our unaudited interim condensed consolidated financial statements and audited consolidated financial statements and accompanying notes thereto included elsewhere in this prospectus. Key factors affecting our results of operations include revenues, cost of revenue, operating expenses and income and taxation.

Non-GAAP Financial Measures

We currently focus on EBITDA to evaluate our business relationships and our resulting operating performance and financial position. EBITDA is defined as net income p

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_31 [2025-04-15 04:36:51 -0400] 1181 Bytes | 313 tokens | Cum: 5148 tkns (64.35% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): lus interest expense, income tax expense, depreciation and amortization.

We believe that EBITDA, viewed in addition to, and not in lieu of, our reported results in accordance with accounting principles generally accepted in the United States (U.S. GAAP), provides useful information to investors.

##TABLE_START Year Ended December 31, 2024 Year Ended December 31, 2023 Net income $ 2,124,976 $ 6,338,750 Interest income (1,523 ) (1,616 ) Interest expense 4,105,198 4,236,149 Taxes 102,085 234,980 Depreciation and amortization 133,334 33,333 EBITDA $ 6,464,070 $ 10,841,596 ##TABLE_END

EBITDA is considered non-GAAP financial measures. EBITDA represents earnings before interest, taxes, depreciation and amortization. Our definition of EBITDA might not be comparable to similarly titled measures reported by other companies.

Results of Operations for the Years Ended December 31, 2024 and Decembe

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_33 [2025-04-15 04:36:53 -0400] 1181 Bytes | 343 tokens | Cum: 5493 tkns (68.66% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): r 31, 2023

During both 2024 and 2023, we focused on developing our currently owned brands into new markets and by product extensions.

Revenue

For the year ended December 31, 2024, we had revenues of $34,834,243 from sales of our products, as compared to revenue of $42,777,633 for the year ended December 31, 2023. This is comprised of the following categories:

##TABLE_START December 31, 2024 December 31, 2023 Nutraceuticals $ 34,817,333 $ 42,753,052 Consumer Goods 16,910 24,581 $ 34,834,243 $ 42,777,633 ##TABLE_END

For the year ended December 31, 2024, our Nutraceuticals revenue consisted of $30,798,145 from our FOCUSfactor brand and $4,019,188 from our Flat Tummy brand, as compared to $37,202,521 and $5,550,531, respectively, for the year ended December 31, 2023.

The decrease in our Nutraceutical category was due to undertaking a rebranding and packaging upgrade for FOCUSfactor t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_35 [2025-04-15 04:36:55 -0400] 1181 Bytes | 309 tokens | Cum: 5804 tkns (72.55% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): hat resulted in customers selling through their existing inventory before bringing in the new packaging. The decrease in the Consumer Goods category is due to normalization of business after the 2019 launch of our online application.

Cost of Sales

For the year ended December 31, 2024, our cost of sales was $11,191,224. Our cost of sales for the year ended December 31, 2023 was $10,697,323. The increase in cost of sales was primarily due to a settlement with a supplier in 2023 resulting in a reduction in cost of sales for 2023.

Gross Profit

Gross profit was $23,643,019, or 68% of revenue for the year ended December 31, 2024, as compared to gross profit of $32,080,310 or 75% of revenue for the same period in 2023, a decrease of $8,437,291 or 26%. The decrease in gross profit is largely related to the decrease in net sales due to the rebranding of FOCUSfactor.

Operating Expenses

Se

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_37 [2025-04-15 04:36:56 -0400] 790 Bytes | 206 tokens | Cum: 6012 tkns (75.15% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): lling and Marketing Expenses

For the year ended December 31, 2024, our selling and marketing expenses were $12,991,431 as compared to $15,188,528 for the year ended December 31, 2023. The decrease is due to management of expenses.

General and Administrative Expenses

For the year ended December 31, 2024, our general and administrative expenses were $4,717,006. For the year ended December 31, 2023, our general and administrative expenses were $6,051,703. The decrease is largely due to management ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SNYR_OUT_39 [2025-04-15 04:37:06 -0400] 6210 Bytes | 1673 tokens | Cum: 7687 tkns (96.09% of 8k)
==========================================================================

This is our set of metrics for Synergy CHC.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+------------------------+
| Volume: 256,570 | Perf Month: -49.58% | Option/Short: No / No | Sales Y/Y TTM: - |
+--------------------+-----------------------+-----------------------+------------------------+
| Avg Volume: 26.91K | Perf Quarter: -60.13% | Short Float: 0.23% | ROE: - |
+--------------------+-----------------------+-----------------------+------------------------+
| Rel Volume: 1.63 | Index: - | Short Ratio: 0.31 | ROI: - |
+--------------------+-----------------------+-----------------------+------------------------+
| RSI (14): 27.85 | Market Cap: 15.67M | Short Interest: 0.01M | Sales Surprise: -2.36% |
+--------------------+-----------------------+-----------------------+------------------------+
| ATR (14): 0.50 | Shs Outstand: 8.54M | Beta: - | EPS Surprise: -90.00% |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA20: -30.51% | Shs Float: 3.66M | Sales Q/Q: -4.95% | P/E: 0.98 |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA50: -44.47% | Inst Own: 10.56% | Sales past 5Y: -3.60% | Earnings: Mar 31 BMO |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA200: -39.39% | Insider Own: 58.15% | Employees: 21 | |
+--------------------+-----------------------+-----------------------+------------------------+
| Perf Week: -11.88% | Insider Trans: 6.72% | Debt/Eq: - | |
+--------------------+-----------------------+-----------------------+------------------------+

The next section covers any insider trading by Synergy CHC officers or majority shareholders (if available).

Inside Trans: Synergy CHC Corp. (SNYR) by Ross Jack (CEO and Chairman) on 2025-01-23
- Common Stock, par value $0.00001 per share: 100 shares at $4.09 (D)
- Common Stock, par value $0.00001 per share: 300 shares at $3.89 (D)
- Common Stock, par value $0.00001 per share: 400 shares at $3.84 (D)
- Common Stock, par value $0.00001 per share: 1300 shares at $4.21 (D)
- Common Stock, par value $0.00001 per share: 700 shares at $4.35 (D)
- Common Stock, par value $0.00001 per share: 500 shares at $4.23 (D)
- Common Stock, par value $0.00001 per share: 600 shares at $3.92 (D)
- Common Stock, par value $0.00001 per share: 500 shares at $4.21 (D)
- Common Stock, par value $0.00001 per share: 950 shares at $4.17 (D)
- Common Stock, par value $0.00001 per share: 800 shares at $4.14 (D)
- Common Stock, par value $0.00001 per share: 1800 shares at $3.91 (D)
- Common Stock, par value $0.00001 per share: 1600 shares at $3.8 (D)
- Common Stock, par value $0.00001 per share: 500 shares at $3.41 (D)
- Common Stock, par value $0.00001 per share: 900 shares at $3.51 (D)
- Common Stock, par value $0.00001 per share: 600 shares at $3.74 (D)
- Common Stock, par value $0.00001 per share: 900 shares at $3.67 (D)
- Common Stock, par value $0.00001 per share: 950 shares at $3.69 (D)
- Common Stock, par value $0.00001 per share: 300 shares at $3.69 (D)
- Common Stock, par value $0.00001 per share: 1200 shares at $3.92 (D)
- Common Stock, par value $0.00001 per share: 300 shares at $4 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.79
Average Volume: 45379.38
30-Day High: 3.58
30-Day Low: 1.75
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Synergy CHC (SNYR).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Synergy CHC.

2) MARKET_SCORE[]
This conversation was initiated because SNYR is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for SNYR.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, SNYR could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect SNYR to increase 50% from its current price of $2.58, say: PRICE_TARGET[3.87]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Synergy CHC.

11) ETHICAL_RATING[]
Rate Synergy CHC’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

SNYR_IN_41 [2025-04-15 04:37:07 -0400] 126 Bytes | 29 tokens | Cum: 7905 tkns (98.81% of 8k)
==========================================================================

====================================
[2025-04-15 04:37:07] # Analysis Completed
Elapsed Time: 37.61 seconds